Chinese Academy of Sciences invested in a round that will be used to take Haihe's anti-tumour therapies further down the clinical path.

China-based cancer therapy developer Haihe Biopharma raised $146.6m yesterday in a funding round featuring Chinese Academy of Sciences Venture Capital Management, which invests on behalf of the eponymous institute.
Drug producers CSPC Pharmaceutical Group and Daehwa Pharmaceutical also participated in the round, as did Huagai Capital, Yingke PE, Hillhouse Capital, Atlas Capital, BioTrack Capital and Elite Capital.
Formed through the March 2018 merger of Haihe Pharmaceutical and RMX Biopharma, Haihe Biopharma is developing anti-tumour drugs and has a…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?